Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Draft Guidelines for Physician-led Clinical Trials
July 22, 2002
- Otsuka Transfers Contract Lab Test Business to BML
July 22, 2002
- BUSINESS NEWS IN BRIEF
July 15, 2002
- Bayer BP Reports Possibility of Removal of Pathogenic Human Prion Protein
July 15, 2002
- AstraZeneca Decides to Provide Iressa before Listing
July 15, 2002
- RELOCATION
July 15, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 15, 2002
- Esmolol, Ferucarbotran Recommended for Approval
July 15, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 15, 2002
- WEBSITE NEWS
July 15, 2002
- Generics of 162 Active Ingredients Included in NHI Price List
July 15, 2002
- Press Seminar
July 15, 2002
- Healthcare Reform to Raise People's Burden by \1.5 Trillion: Korosho
July 15, 2002
- Takeda, J&J to Promote Tylenol for Use on Empty Stomach
July 15, 2002
- Outline for Intellectual Property Strategy Finalized
July 15, 2002
- Asahi Beer Pham Merges Its Drug and Food Subsidiaries
July 15, 2002
- REGULATORY NEWS IN BRIEF
July 15, 2002
- OTC NEWS IN BRIEF
July 15, 2002
- National Nagano Hospital to Encourage Use of Generics
July 15, 2002
- RDKK Aims at Sales of \60 Bil., 15% Share in 2006
July 15, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…